$ADVM Strange...."Given the encouraging robust anatomical response from patients in the first cohort, we will begin dosing patients in the second cohort at a lower dose of 2 x 10^11 vg/eye, instead of dose escalating as previously planned.”
This has to be the most clever way to continue a clinical trial without escaping clinical hold, while disguising it as a release off of clinical hold, that I've ever seen...